|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 791.06 USD | -1.07% |
|
-4.44% | +36.04% |
| 03:08pm | Eli Lilly Says Imlunestrant Improved Progression-Free Survival in Phase 3 Breast Cancer Study | MT |
| 12-10 | Lilly Will Test Obesity Drugs on Addiction, CEO Says | MT |
| Capitalization | 720B 685B 635B 565B 1,020B 61,098B 1,130B 7,908B 2,919B 25,088B 2,703B 2,645B 109,481B | P/E ratio 2024 * |
63x | P/E ratio 2025 * | 37.1x |
|---|---|---|---|---|---|
| Enterprise value | 741B 705B 654B 581B 1,050B 62,892B 1,163B 8,140B 3,005B 25,824B 2,782B 2,722B 112,695B | EV / Sales 2024 * |
16.2x | EV / Sales 2025 * | 12.5x |
| Free-Float |
99.81% | Yield 2024 * |
0.65% | Yield 2025 * | 0.75% |
More valuation ratios
* Estimated data
More news
Last Transcript: Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.98% | ||
| 1 week | -4.44% | ||
| Current month | -0.29% | ||
| 1 month | -4.73% | ||
| 3 months | -13.88% | ||
| 6 months | -8.41% | ||
| Current year | +36.04% |
1 week
789.00
841.00
1 month
711.40846.46
Current year
579.05972.53
1 year
561.65972.53
3 years
231.87972.53
5 years
117.06972.53
10 years
64.18972.53
| Director | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 2016-12-31 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 47 | 2024-09-08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 64 | 2004-12-31 |
Ralph Alvarez
BRD | Director/Board Member | 68 | 2009-03-31 |
| Director/Board Member | 52 | 2011-12-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 20 M€ | +16.14% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -1.07% | -4.44% | +35.78% | +219.09% | 720B | ||
| +0.06% | +0.35% | +16.96% | +105.41% | 488B | ||
| -1.13% | -1.69% | -4.60% | -12.19% | 359B | ||
| -0.78% | -0.95% | +15.56% | +38.16% | 310B | ||
| -0.12% | -0.22% | -3.09% | +37.77% | 255B | ||
| +0.65% | +0.63% | +0.39% | -31.97% | 231B | ||
| +0.41% | +0.88% | +4.71% | +28.18% | 208B | ||
| -0.94% | -2.28% | +2.89% | +18.12% | 201B | ||
| -0.54% | -1.00% | +1.23% | +30.32% | 148B | ||
| -0.70% | +0.75% | -11.24% | -53.95% | 145B | ||
| Average | -0.40% | -1.53% | +5.86% | +37.89% | 306.61B | |
| Weighted average by Cap. | -0.48% | -1.53% | +11.95% | +73.40% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 45.64B 43.44B 40.26B 35.81B 64.64B 3,873B 71.63B 501B 185B 1,590B 171B 168B 6,940B | 58.58B 55.75B 51.67B 45.96B 82.96B 4,971B 91.94B 643B 238B 2,041B 220B 215B 8,908B |
| Net income | 11.34B 10.8B 10B 8.9B 16.06B 963B 17.8B 125B 45.99B 395B 42.58B 41.67B 1,725B | 19.57B 18.63B 17.26B 15.35B 27.72B 1,661B 30.72B 215B 79.35B 682B 73.47B 71.89B 2,976B |
| Net Debt | 21.13B 20.12B 18.64B 16.58B 29.93B 1,794B 33.17B 232B 85.69B 736B 79.34B 77.63B 3,214B | 13.11B 12.48B 11.56B 10.28B 18.57B 1,113B 20.58B 144B 53.15B 457B 49.22B 48.16B 1,993B |
More financial data
* Estimated data
Employees
43,000
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-11 | 792.29 $ | -0.91% | 342,506 |
| 24-12-10 | 799.58 $ | -0.50% | 2,695,247 |
| 24-12-09 | 803.58 $ | -2.80% | 3,175,956 |
| 24-12-06 | 826.71 $ | +0.13% | 3,047,127 |
| 24-12-05 | 825.62 $ | -0.51% | 2,423,388 |
Delayed Quote Nyse, December 11, 2024 at 09:48 am
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
799.58USD
Average target price
984.05USD
Spread / Average Target
+23.07%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition